Traders stick with Nektar Therapeutics

By
A A A

Traders are sticking with Nektar Therapeutics as the drug developer consolidates at multiyear highs.

optionMONSTER's Heat Seeker monitoring system detected the purchase of 7,500 October 12 calls for $1.80. A matching number of September 12 calls was sold at the same time for $1.20 against previous open interest.

We cited the buying in the September contracts earlier this month for $1.25 to $1.35, and yesterday's transaction allowed them to extend that bet position by one month at a cost of $0.60. See our Education Section for more on how to manage trades more effectively with options.

NKTR rose 3.05 percent to $12.16 yesterday, and has roughly doubled since late November. The company has a wide array of potential medicines under development, including at least five in late-stage trials. It's spent the last two months consolidating at levels last seen in early 2011.

Total option volume was 19 times greater than average in Wednesday's session, with calls outnumbering puts by a bullish 33-to-1 ratio.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright © 2010 OptionMonster® Holdings, Inc. All Rights Reserved.


This article appears in: Investing , Options

Referenced Stocks: NKTR

optionMONSTER

optionMONSTER

More from optionMONSTER:

Related Videos

Stocks

Referenced

Most Active by Volume

80,672,062
  • $15.11 ▼ 7.47%
66,542,096
  • $17.01 ▼ 0.12%
55,706,072
  • $23.65 ▲ 21.22%
52,954,494
  • $14.70 ▼ 10.69%
50,243,980
  • $14.70 ▼ 7.49%
47,401,468
  • $100.11 ▼ 0.64%
43,293,183
  • $4.95 ▼ 5.17%
36,328,194
  • $2.79 ▼ 1.41%
As of 9/29/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com